VIM and cancer: CNa 29 significantly reduced filamin A cleavage, vimentin expression, TWIST1 transcription, and the expressions of genes related to cancer stemness and increased the efficacy of doxorubicin, a chemotherapy drug commonly used for TNBC in clinical settings (Figures 6D,E and S11B–D).